UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000012668
Receipt No. R000014812
Official scientific title of the study Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
Date of disclosure of the study information 2013/12/25
Last modified on 2017/06/29 (Ver. 6)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
Title of the study (Brief title) Simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
Region
Japan

Condition
Condition chronic infection with hepatitis C virus
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes - Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure.
- Investigating the factors for sustained virological response.
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Simeprevir plus Peg-IFN combination therapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Hemodialysis patients
2) Patients with chronic infection with hepatitis C virus genotype 1 and more than 5 log IU/ml
Key exclusion criteria 1) Patients with co-infection with hepatitis B virus or human immunodeficiency virus or alcoholic liver disorder or autoimmune hepatitis.
2) Patients with uncompensated cirrhosis or hepatic failure
3) Patients with multiple organ failure or immunological deficiency
4) Patients with severe depression or past history of psychiatric disorder
5) Patients in pregnancy or lactating or patients who expect to become pregnant
Target sample size 45

Research contact person
Name of lead principal investigator Tetsuo Takehara
Organization Osaka University Graduate school of Medicine
Division name Department of Gastroenterology and Hepatology
Address Yamadaoka 2-2, Suita, Osaka, Japan
TEL 06-6879-3621
Email takehara@gh.med.osaka-u.ac.jp

Public contact
Name of contact person Naoki Hiramatsu
Organization Osaka University Graduate school of Medicine
Division name Gastroenterology and Hepatology
Address Yamadaoka 2-2, Suita, Osaka, Japan
TEL 06-6879-3621
Homepage URL
Email hiramatsu@gh.med.osaka-u.ac.jp

Sponsor
Institute Osaka University Graduate school of Medicine
Institute
Department

Funding Source
Organization Osaka University Graduate school of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2013 Year 12 Month 25 Day

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 11 Month 05 Day
Anticipated trial start date
2013 Year 12 Month 25 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2013 Year 12 Month 24 Day
Last modified on
2017 Year 06 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000014812